CBG

(Cannabigerol)

 

Studies are beginning to show that is minor cannabinoid has the potential to aid with IBS, MS and nausea. As always, please consult your doctors prior to beginning a cannabis regimen.

 

Cannabigerol Is a Potential Therapeutic Agent in a Novel Combined Therapy for Glioblastoma

Colon carcinogenesis is inhibited by the TRPM8 antagonist cannabigerol, a Cannabis-derived non-psychotropic cannabinoid

A Cannabigerol quinone alleviates neuroinflammation in a chronic model of multiple sclerosis

A Cannabigerol derivative suppresses immune responses and protects mice from experimental autoimmune encephalomyelitis

Beneficial effect of the non-psychotropic plant cannabinoid Cannabigerol on experimental inflammatory bowel disease

THE PHARMACOLOGICAL CASE FOR CANNABIGEROL (CBG)

The Role of 5-HT1A Receptor, and Nausea and Vomiting Relief by Cannabidiol (CBD), Cannabidiolic Acid (CBDA), and Cannabigerol (CBG)

Differential effectiveness of selected non-psychotropic phytocannabinoids on human sebocyte functions implicates their introduction in dry/seborrhoeic skin and acne treatment

Effect of Non-psychotropic Plant-derived Cannabinoids on Bladder Contractility: Focus on Cannabigerol

Cannabidiol in medicine: a review of its therapeutic potential in CNS disorders

ng the Hidden Antibiotic Potential of Cannabis

The anti-inflammatory effects of Cannabidiol and Cannabigerol alone, and in combination

A review of Cannabigerol and its vast translational potential

Antioxidant and Neuroprotective Effects Induced by Cannabidiol and Cannabigerol in Rat CTX-TNA2 Astrocytes and Isolated Cortexes

CBG, CBD, Δ9-THC, CBN, CBGA, CBDA and Δ9-THCA as antioxidant agents and their intervention abilities in antioxidant action

The Pharmacological Case for Cannabigerol

Medical cannabis use in Canada and its impact on anxiety and depression: A retrospective study